ArticleJournal of biomolecular structure & dynamics2021
Repurposing cefuroxime for treatment of COVID-19: a scoping review of
Article in Journal of biomolecular structure & dynamics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 51 citations in OpenAlex.
- Impact of the COVID-19 pandemic on the consumption of antibiotics and the emergence of AMR: case study in a general hospital.Frontiers in public health · 2025Article
- Repositioning of Antibiotics in the Treatment of Viral Infections.Current microbiology · 2024Review
- Potential Drugs in COVID-19 Management.Current medicinal chemistry · 2024Review
- Therapeutic Management with Repurposing Approaches: A Mystery During COVID-19 Outbreak.Current molecular medicine · 2024Review
- Developing a SARS-CoV-2 main protease binding prediction random forest model for drug repurposing for COVID-19 treatment.Experimental biology and medicine (Maywood, N.J.) · 2023Article
- Review
- Article
- Identification of novel inhibitors for SARS-CoV-2 as therapeutic options using machine learning-based virtual screening, molecular docking and MD simulation.Frontiers in molecular biosciences · 2023Article
- Increasing Consumption of Antibiotics during the COVID-19 Pandemic: Implications for Patient Health and Emerging Anti-Microbial Resistance.Antibiotics (Basel, Switzerland) · 2022Review
- Exploring the anti-SARS-CoV-2 main protease potential of FDA approved marine drugs using integrated machine learning templates as predictive tools.International journal of biological macromolecules · 2022Article
- Review
- In Silico Screening of Bioactive Compounds of Representative Seaweeds to Inhibit SARS-CoV-2 ACE2-Bound Omicron B.1.1.529 Spike Protein Trimer.Marine drugs · 2022Article
- A network representation approach for COVID-19 drug recommendation.Methods (San Diego, Calif.) · 2022Article
- Structural biology of SARS-CoV-2: open the door for novel therapies.Signal transduction and targeted therapy · 2022Review
- A Case-Control of Patients with COVID-19 to Explore the Association of Previous Hospitalisation Use of Medication on the Mortality of COVID-19 Disease: A Propensity Score Matching Analysis.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Molecular docking, DFT analysis, and dynamics simulation of natural bioactive compounds targeting ACE2 and TMPRSS2 dual binding sites of spike protein of SARS CoV-2.Journal of molecular liquids · 2021Article
- In Silico Mutagenesis-Based Remodelling of SARS-CoV-1 Peptide (ATLQAIAS) to Inhibit SARS-CoV-2: Structural-Dynamics and Free Energy Calculations.Interdisciplinary sciences, computational life sciences · 2021Article
- Tracking the interaction between single-wall carbon nanotube and SARS-Cov-2 spike glycoprotein: A molecular dynamics simulations study.Computers in biology and medicine · 2021Article
- In silico and in vitro evaluation of kaempferol as a potential inhibitor of the SARS-CoV-2 main protease (3CLpro).Phytotherapy research : PTR · 2021Article
- Repurposing of antibiotics for clinical management of COVID-19: a narrative review.Annals of clinical microbiology and antimicrobials · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the causative agent of Coronavirus disease 19 (COVID-19), is a novel human Coronavirus that is responsible for about 300,000 deaths worldwide. To date, there is no confirmed treatment or vaccine prevention strategy against COVID-19. Due to the urgent need for effective treatment, drug repurposing is regarded as the immediate option. Potential drugs can often be identified via
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.